Frank T. Gentile, Ph.D.
Frank Gentile joined Third Rock Ventures in 2015 to focus on research and development opportunities throughout the portfolio. He has played key roles in launching and building some of our portfolio companies, including:
- Board member and interim chief operating officer of Casma Therapeutics
Frank brings nearly 25 years of experience working with pharmaceutical and biotechnology companies, and spent the past 12 years with Tekla Capital Management LLC, formerly Hambrecht & Quist Capital Management LLC, where he most recently served as senior vice president. In this role, Frank oversaw and executed biotechnology and healthcare investments in public and private companies in the areas of oncology, cardiovascular, infectious diseases, rare diseases, medical devices and diagnostics and discovery tools and served as a member of the board of directors in several private companies. Prior to Tekla, Frank oversaw technology research and development programs while serving as vice president, technology program management at Millennium Pharmaceuticals and earlier in his role as vice president, product development at Curis. Before that, Frank served as vice president, program management at Reprogenesis, Inc., where he was responsible for all program management, partnership and intellectual property functions. Earlier in his career, Frank held roles of increasing responsibility at CytoTherapeutics, Inc., where he most recently served as associate director, R&D program management. He currently serves as an adjunct associate professor of pharmacology and biotechnology in the division of biology and medicine at Brown University. Frank completed his post-doctoral work at the Swiss Federal Institute of Technology in Zurich and received his Ph.D. in chemical engineering from MIT where he was a G.E. Fellow. Additionally, Frank holds a B.E. in chemical engineering from The Cooper Union for the Advancement of Science and Art.
Frank is a certified 4th degree black belt instructor in Tae Kwon Do.